PORTLAND, IA, UNITED STATES, January 9, 2025 /EINPresswire / -- The factors that are anticipated to impede the growth of the global nucleic acid therapeutics market during the forecast period include, ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.TRc4SPmX.js ...

Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. The San Diego company has guided for full-year revenue ...

Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, USA ...

Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...

Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response to nucleic acids, according to a recent study.

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks ...

Principal Financial Group Inc. lessened its stake in shares of Qiagen (NYSE:QGEN – Free Report) by 12.0% in the 3rd quarter, ...

Morgan Stanley reiterated their equal weight rating on shares of Qiagen (NYSE:QGEN – Free Report) in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a ...